Lenalidomide has been developed as an immunomodulatory derivative of the parent compound, thalidomide. Despite its significant clinical efficacy and presumed immune effect, no human studies to date have documented these properties. In this study, we demonstrate these immune outcomes in two ways.
INTRODUCTION
Thalidomide was the first "novel" drug introduced for the treatment of multiple myeloma and has demonstrated considerable antitumor activity through multiple mechanisms, including via the tumor microenvironment through inhibition of angiogenesis and tumor necrosis factor (TNF)-α. It also increases lymphoid immune function by increasing natural killer (NK) cell numbers and antibody-dependent cell-mediated cytotoxicity, [3] [4] [5] and augments NK T-cell numbers and function through increases in CD1d-mediated presentation of glycolipids. 6 Lenalidomide enhances T-cell cytokine production and proliferation by augmenting activator protein (AP)-1 transcriptional activity, 7 reducing the inhibitory effect of cytotoxic T-lymphocyte antigen (CTLA) -4, 8 and possibly reducing the generation of regulatory T-cells (T regs ). 9 This activity suggests that a major mechanism of lenalidomide clinical activity is through its immunomodulatory role within the tumor microenvironment. 10 Although utilized in myeloma, the impact of single-agent lenalidomide on antigen-specific immune responses in myeloma patients has not been formally examined. 11, 12 Previous studies have indicated that lenalidomide has the potential to enhance immune responses both in vitro 5, 13 and in patients with advanced tumors. 14, 15 In addition, while vaccines can induce immune-responses Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-11-1221 in myeloma patients, the lack of a measurable clinical benefit is largely due to the profound tumor-associated immune tolerance of patients. 16 Thus, current strategies to improve myeloma vaccines must emphasize modulation of the immune system. This study was designed to determine whether lenalidomide could augment vaccine responses and elicit myeloma-specific immune responses when used in combination with the pneumococcal 7-valent conjugate vaccine (PCV; Prevnar ® , Wyeth Pharmaceuticals Inc., Philadelphia, PA), a vaccine conjugated to the modified diphtheria toxin (CRM197).
PATIENTS AND METHODS

Patient Eligibility
This was an open-label, two-cohort study in which all patients received lenalidomide in combination with two PCV vaccinations in one of two randomly assigned vaccine schedules. PCV was chosen because of its ability to invoke both T-cell dependent anti-pneumococcal antibody responses and anti-CRM197 T-cell responses.
17
Patients with relapsed myeloma following 1 to 3 prior therapies were included in this study. The study was approved by the institutional review board at the Johns Hopkins Medical Institutions and all patients provided written informed consent. 6 21 of each 28-day cycle, for at total of 6 cycles. Cohort A received their first vaccination 2 weeks prior to starting lenalidomide and their second on day 14 of cycle 2 (Fig 1) . Cohort B received their first vaccination on day 14 of cycle 2 and their second on day 14 of cycle 4. Steroids were prohibited to avoid immunosuppression. Lenalidomide dose reductions were based on standard clinical practice: 20 mg (dose level −1); 15 mg (level −2); 10 mg (level −3); and 5 mg (level −4). Candida-specific, delayed type hypersensitivity (DTH) was administered at enrollment, prior to each vaccination, and 6 weeks after the last vaccination. Erythema and induration to Candida were recorded at 48 hours by measuring the widest diameters in two perpendicular directions. For purposes of immune monitoring, blood and bone marrow samples were obtained as indicated in the study schema. Samples were obtained at baseline in both cohorts: prior to the first Prevnar administration in Cohort A or prior to initiation of lenalidomide in Cohort B. Subsequent sample time points were prior to the second vaccine and 6 weeks after the second vaccine.
Response Assessment
The clinical response to lenalidomide was assessed after each cycle. Patients with a ≥50% decrease in the monoclonal paraprotein levels were defined as responders (R). Patients whose myeloma progressed by an increase in monoclonal paraprotein levels of ≥25% were defined as progressors (PD). Stable disease (SD) was defined as a less than 50% decrease in their monoclonal protein levels.
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Serological Responses to PCV
Serum IgG levels against 4 (6B, 14F, 19F, and 23F) of the 7 PCV serotypes were measured by enzyme-linked immunosorbent assay as previously described. 18, 19 Titers were reported in µg/mL by interpolating Abs 450 values in the doseresponse curve of the pneumococcal reference standard serum 89SF.
Antigen-Specific T-Cell Responses
Peripheral blood lymphocytes (PBL) and bone marrow (BM) cells were thawed in AIM-V media (Invitrogen, Carlsbad, CA), labeled with carboxyfluorescein succinimidyl ester (CFSE; Invitrogen) and incubated for 10 minutes at 37°C. Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-11-1221 presence or absence of the cell lysates, harvested, and stained with anti-CD3 (BD-Biosciences) and IFN-γ (e-Biosciences) prior to analysis by flow cytometry.
Flow Cytometry
Cells were stained for cell surface expression of CD3, CD4, CD8, CD40L, CTLA4, CD14, CD19, CD26, CD56, and CD11c (BD-Biosciences). Cells were enumerated utilizing a FACS Calibur and analyzed utilizing CellQuest Pro software. Intracellular staining for FOXP3 (e-Biosciences), IFN-γ, and IL-17 was performed by adding GolgiPlug (BD-Biosciences) per manufacturer's recommendations. Extracellular staining was performed as described above.
Statistics
P-values were determined utilizing the Graph-Pad t-test online software.
RESULTS
A total of 22 patients were enrolled, 11 in each cohort. Patients were deemed evaluable if they received both PCV vaccinations; 1 patient in Cohort A and 4 in Cohort B showed evidence of disease progression while on study and were not included in this analysis. Characteristics of the patients are summarized in Table   1 .
One reliable measure of systemic immunity is the ability of an individual to generate a DTH reaction to the antigen of interest. As such, Candida DTH 
PCV-Specific Immune Responses
One of the benefits of utilizing the PCV vaccine lies in the ability to measure both humoral responses to pneumococcal antigens as well as the cellular immune response to the carrier molecule, the diphtheria-derived protein, CRM-197. To examine whether PCV-specific responses could be generated and maintained, or augmented by lenalidomide, antibody titers were examined for 4 of the 7 serotypes present in PCV (Fig 2B and 2C) . In Cohort A, antibody titers were stable or decreased in both blood and BM across the vaccination schedule. In contrast, antibody titers in Cohort B showed a continuous rise across the vaccination schedule.
To determine the potential of lenalidomide in augmenting antigen-specific T-cell immunity, CRM197 responses were determined at baseline and after each vaccination. In the peripheral blood, Cohort A showed no increase in CRM197-specific T-cell responses in the blood (1.2 fold above baseline) (Fig 2D) . In contrast, Cohort B displayed increases at both time points, with a maximal 4.7-fold increase observed after the first vaccination (Fig 2D) . Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-11-1221 Overall measures of antigen-specific T-cell responses were significantly greater in the BM than in the blood (Fig 2E) . This likely reflects the ability of the BM to serve as a reservoir of antigen experienced T cells. After the first vaccination, CRM-197 specific T cell responses were greater in the BM than the blood (Cohort A 7.5% v 2.9%, respectively, P = .001; and Cohort B 11.1% v 5.2%, P = .002) (Fig 2D,E) . Consistent with the data obtained in the blood, PCVspecific T-cell responses were greater in Cohort B than Cohort A. Interestingly, the antigen-specific response to the second vaccination was not blunted in Cohort A but remained stable in Cohort B. To investigate this, we examined the CRM197-specific T-cell responses based on the patients' clinical responses.
Patients with progressive disease (PD) showed a blunted antigen-specific response to the first vaccination when compared with responders (blood 2.6% v 4.5%, respectively, P = .32; and BM 5.8% v 9.6%, P = .006). As expected, responses to the second vaccination was further decreased in progressors, stable in patients with stable disease, and increased in responders. Cohort A had 30% progressors and 60% with stable disease. Cohort B had 14% progressors and 28% with stable disease. This marked difference in clinical response rates to lenalidomide appears to be associated with corresponding differences in antigen specific immune reactivity where disease progression significantly Fig 3B,F, H ). These changes suggest that antigen specific T cell activation correlates with overall disease response which was greater in Cohort B. Th17 cells were also reduced in the BM of Cohort B while their levels in Cohort A remained unchanged ( Fig   3B) .
Research. DOI: 10.1158 /1078 -0432.CCR-11-1221 Other immune parameters such as dendritic cell populations and NK populations did not appear affected by treatment. However, increases in NKmediated cell lysis were observed in both Cohorts A and B (Supplemental Fig 1) .
Myeloma-Specific Immunity
We examined whether tumor specific immunity could be detected in our patients.
Due to the paucity of autologous tumor available in this study and the abundance of antigen-presenting cells (APCs) in the BM capable of capturing, processing and presenting antigen, myeloma-specific immunity was determined utilizing APCs pulsed with allogeneic myeloma cell lysates and the specificity of this response was assessed by comparing the T cell reactivity towards APCs pulsed with the irrelevant bladder cancer cell line (SW780). Absence of non-specific IFN-γ production in the presence of SW780 confirms the absence of non-specific allo-reactivity and the utility of this assay. The tumor-specific immune response increased in Cohort B upon completion of the study with an average antigenspecific CD3 cell percentage of 7.7% up from a baseline of 2.25% (P = .003) (Fig   4A-C) . In contrast, Cohort A showed no significant induction of a tumor specific response.
DISCUSSION
This is the first study in humans to examine both the general and antigen-specific This study was designed to demonstrate whether vaccine responses could be augmented through the addition of the immunomodulatory drug, lenalidomide.
The study utilized the polyvalent pneumococcal vaccine, Prevnar®, because of our ability to measure both humoral and cellular responses. In this study we were able to confirm this synergy by demonstrating increases in the antibody titers and higher antigen specific T cell responses with simultaneous administration of vaccine and lenalidomide. These in vivo findings confirm the numerous reports describing the immunomodulatory effects of lenalidomide. 8, 22, 23 Considering the profound immune dysfunction associated with myeloma, 24 strategies to overcome these obstacles should increase immune responsiveness to infectious vaccines. This could reduce infectious complications which currently represent a major morbidity in myeloma. Unlike most other studies published to date, our immune analysis primarily focused on the BM for two major reasons. First, this represents the tumor microenvironment and as such the site in which changes in immune function will have the most significant biologic and clinical effects. Second, the BM is unique site that enriches for antigen-specific T cell responses. 26, 29 This is confirmed in our study by the greater percentage of antigen specific T cells in both cohorts in the BM compared to blood (Fig 2D and E) and by the greater changes in overall T cell function seen in the BM in response to lenalidomide (Fig 3B) .
Vaccine specific immune responses appeared greater when vaccine was Vaccine-specific responses were primed with PCV to a greater extent when administered concomitantly with lenalidomide (Cohort B) (Fig 2C and D) .
Interestingly, the T cell responses to the second vaccine administered 8 weeks later was reduced in Cohort A and stable in Cohort B. This is likely explained by accompanying clinical response. More patients showed stable or progressive disease in Cohort A compared to Cohort B (90% vs 43%). In fact, an analysis of the patients based on response rates showed a reduction in T cell responses to PCV in progressors and an increase in PCV T cell responses in patients achieving at least a partial response (data not shown). Similarly, IFNγ and CD40L expression was also increased in Cohort B as would be expected with priming of an antigen specific T cell response.
The role of Th17 cells within the BM microenvironment also warrants discussion. Cohort B showed a significant decline in Th17 in the BM whereas these cells initially decreased and then increased in Cohort A. Myeloma-induced production of IL-6 in the presence of transforming growth factor (TGF)-β skews naïve CD4 cells away from T regs towards a Th17 phenotype. Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-11-1221 intrinsic immune-mediated anti-myeloma activity of lenalidomide, it is difficult to separate the antitumor effects from its effect as a vaccine immune-modulator.
However, we showed that increased immune responsiveness correlated with both increased vaccine-specific immunity (Fig 2D) . This strongly implies an immunomodulatory effect of lenalidomide and not just a tumor-specific cytotoxic effect of the drug. We also observed other immunomodulatory aspects of lenalidomide that underscore its positive immune effects, including an increase in NK cytolytic activity and T CM in both the blood and BM.
PCV in combination with lenalidomide generated interesting and unexpected results. This vaccine was chosen because of its ability to prime both humoral and cellular responses that would enable us to examine both arms of the immune response in patients treated with lenalidomide. We have shown greater increases in both pneumococcal antibody titers as well as CRM197-specific T-cell responses in Cohort B, which received both vaccinations while on lenalidomide. However, other findings warrant discussion. First, the T-cellspecific responses were greater in the BM than in the blood with more than double the percentage of antigen-specific T-cells. This finding significantly underscores the uniqueness of the BM as an immune niche of antigen-specific Tcells. 34, 35 Considering that the operative immunosuppressive mechanisms are likely to be greatest within the tumor microenvironment, the augmented immune responses in the BM compared with the blood of myeloma patients are even more significant. Second, the generation of myeloma-specific immunity upon DOI: 10.1158 /1078 -0432.CCR-11-1221 completion of vaccination was statistically significant in Cohort B whereas it was negligible in Cohort A. The average daily dose of lenalidomide was equivalent in both groups (Cohort A 21.6 mg/day v Cohort B 19.2 mg/day) as was the overall tumor burden. The only appreciable differences between these two groups were the vaccination schedules and clinical responses to lenalidomide treatment.
In summary, several conclusions can be made from this initial pilot study. Comparisons in which the p value is <0.05 is indicated by (*). Comparisons in which the p value is <0.05 is indicated by (*). Post Vac2 Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-11-1221 
